Cite
Igarashi K, Kawaguchi K, Kiyuna T, et al. Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget. 2017;8(44):75874-75880doi: 10.18632/oncotarget.16548.
Igarashi, K., Kawaguchi, K., Kiyuna, T., Murakami, T., Miwa, S., Nelson, S. D., Dry, S. M., Li, Y., Singh, A. S., Kimura, H., Hayashi, K., Yamamoto, N., Tsuchiya, H., Eilber, F. C., & Hoffman, R. M. (2017). Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget, 8(44), 75874-75880. https://doi.org/10.18632/oncotarget.16548
Igarashi, Kentaro, et al. "Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model." Oncotarget vol. 8,44 (2017): 75874-75880. doi: https://doi.org/10.18632/oncotarget.16548
Igarashi K, Kawaguchi K, Kiyuna T, Murakami T, Miwa S, Nelson SD, Dry SM, Li Y, Singh AS, Kimura H, Hayashi K, Yamamoto N, Tsuchiya H, Eilber FC, Hoffman RM. Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget. 2017 Mar 24;8(44):75874-75880. doi: 10.18632/oncotarget.16548. eCollection 2017 Sep 29. PMID: 29100276; PMCID: PMC5652670.
Copy
Download .nbib